Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2010

Sigma Life Science and SwitchGear Genomics to Develop miRNA Target-Validation System

  • Sigma Life Science and SwitchGear Genomics signed a deal to develop and distribute an miRNA target reporter system.

    Use of Sigma's patented lentiviral technology is expected to allow the SwitchGear GoClone™ miRNA target sets to be used in a range of cell types including primary cells and stem cells.

    “We believe that combining unique technologies from SwitchGear Genomics with Sigma's industry-leading lentiviral technology and production capabilities will enable researchers to study miRNA function and gene regulation on an unprecedented scale,” says Nathan Trinklein, Ph.D., CEO and co-founder of SwitchGear Genomics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »